Mitochondria are double-membrane-bound organelles that are essential for cellular energy production. A fundamental question in eukaryotic cell biology is how the biogenesis of mitochondria is achieved and regulated

Lead Research Organisation: University College London
Department Name: UNLISTED

Abstract

Mitochondria are key parts of the cell whose central role is to produce energy in a suitable form for many biological processes. They are also involved in programmed cell death, and in maintaining appropriate levels of calcium in cells. These activities require mitochondria to communicate with the cell nucleus. Disruption of mitochondrial function can lead to a broad range of human diseases including diabetes, neurodegenerative disorders, obesity, cancer and premature ageing. Therefore, a full understanding of the basic processes in mitochondria is needed to identify the causes and consequences of mitochondrial malfunction and to enable us to design new therapies that compensate for or correct such faults. This programme will study how mitochondria are made and how their function responds to the changing requirements of the cell during growth and development.

Technical Summary

Mitochondria are double-membrane-bound organelles that are essential for cellular energy production. A fundamental question in eukaryotic cell biology is how the biogenesis of mitochondria is achieved and regulated. The process requires the targeting, import and assembly of over 1500 proteins encoded in nuclear DNA. Because mitochondria also contain their own DNA (mtDNA), which in human contributes 13 key components of the energy production apparatus, bidirectional communication between the nucleus and the mitochondria is essential to produce the desired mitochondrial activity. Our knowledge of nucleus to mitochondria (anterograde) signalling pathways coordinating mitochondrial biogenesis is expanding rapidly, and is known to involve the actions of three factors: AMP kinase, Sirt1 and PGC1a. In contrast, the characterization of the key mitochondrial factors that contribute to the regulation of biogenesis, as well as factors involved in the retrograde response (signalling from mitochondria to the nucleus) is much more limited.

Recently my group has discovered a mitochondrial protein, MPV17, with the intrinsic capacity to stimulate mitochondrial function. MPV17 is an inner mitochondrial membrane protein of unknown function, which belongs to a small family of conserved proteins. In 2006, the identification of MPV17 as the gene responsible for a form of mitochondrial DNA depletion syndrome (MDS) linked its protein product to mtDNA maintenance in vivo. Mitochondrial DNA defects were established as a cause of human disease 25 years ago, and yet there is still much that remains obscure about mtDNA maintenance. In animals and plants almost nothing is known about the anchoring, segregation or transmission of mtDNA. Furthermore, mitochondrial (DNA) dysfunction is also implicated in several common disorders, such as neurodegenerative disease, metabolic syndrome and obesity. Thus the functional characterization of proteins causing mitochondrial disease, such as MPV17, is critical to a full understanding of the role of mitochondria in human health, and the design of rational therapeutic strategies. An ability to stimulate mitochondrial biogenesis is widely recognised as the best immediate prospect for treating mitochondrial dysfunction. Hence, the new finding of MPV17’s effect on mitochondrial biogenesis provides a major new target for this approach, which will be best exploited with knowledge of its mechanism of action.

The plan is to elucidate MPV17’s mechanism of action by dissecting the protein and its partners, studying its pathological variants and the regulation of MPV17 gene expression. Specific aims are: 1) To determine the functional and physiological impacts of MPV17 ablation and mutation via proteomic and metabolite profiling of mutant cell lines and an Mpv17 knockout mouse. Fibroblast deficient cell lines, DG75 mutant and a knockout mouse model for MPV17 are already providing us with material for analysis, and they will be used in the future for transcriptomic, proteomic and metabolomic analyses, and for interventions designed to ameliorate its loss. 2) To characterize MPV17’s protein partners by affinity purification and use truncated forms of the protein to identify the key elements needed for these protein-protein interactions. 3) To dissect the stimulatory effects of MPV17 on mitochondrial biogenesis via metabolic, proteomic, and ultrastructure analyses.

Our studies of MPV17 have led to the realization that the metabolic conditions for cell growth have a major impact on mitochondrial function. We have identified nutrient growth regimes that stimulate mitochondrial protein synthesis while repressing protein synthesis in the cytosol. Therefore we predict that some mechanisms of stimulating mitochondrial capacity will repress cytosolic protein synthesis and thereby arrest cell growth and division.

People

ORCID iD

Publications

10 25 50
publication icon
Aiestaran-Zelaia I (2022) 2 deoxy-D-glucose augments the mitochondrial respiratory chain in heart. in Scientific reports

publication icon
Akman G (2016) Pathological ribonuclease H1 causes R-loop depletion and aberrant DNA segregation in mitochondria. in Proceedings of the National Academy of Sciences of the United States of America

publication icon
Baechler SA (2019) Beyond the unwinding: role of TOP1MT in mitochondrial translation. in Cell cycle (Georgetown, Tex.)

publication icon
De La Casa-Fages B (2019) Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism. in Movement disorders : official journal of the Movement Disorder Society

publication icon
De La Casa-Fages B (2019) Reply to: "Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion". in Movement disorders : official journal of the Movement Disorder Society

publication icon
Durigon R (2018) LETM1 couples mitochondrial DNA metabolism and nutrient preference. in EMBO molecular medicine

Related Projects

Project Reference Relationship Related To Start End Award Value
MC_PC_13029/1 23/01/2013 31/08/2016 £184,168
MC_PC_13029/2 Transfer MC_PC_13029/1 01/09/2016 31/01/2019 £1,042,186
 
Description Bologna, Italy
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a guidance/advisory committee
Impact PMID: 32898308
 
Description ENMC, Heemskerk, The Netherlands.
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a guidance/advisory committee
 
Title New sequencing method 
Description The new method is able to determine the identity of the embedded ribonucleotides incorporated in DNA. We have used the new method to study the ribonucleotide incorporation in mitochondrial DNA in health and disease state. 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact The method has allowed the identification of a new mtDNA abnormality, which we predict to be a feature of many disorders in which mitochondrial function is impaired 
 
Title small molecules 
Description Identification of small molecules that purge the cells of mutant mitochondrial genome and restore mitochondrial function 
Type Of Material Technology assay or reagent 
Year Produced 2021 
Provided To Others? Yes  
Impact One of the molecules tested in control animal increases mitochondrial functionality. Currently, the team is preparing a clinical trial to test the effect of the compound on a cohort of patients with mitochondrial DNA disorders. 
 
Description Elucidating the function of MPV17p 
Organisation Francis Crick Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution We isolated RNA from Mpv17 WT and KO mouse tissues
Collaborator Contribution Transcriptomic analysis of Mpv17 WT and KO mouse tissues
Impact Signalling pathways and compensatory mechanisms associated to the tissue-specific Mpv17 dysfunction
Start Year 2016
 
Description Elucidating the role of Mpv17 in nucleotide metabolism 
Organisation Vall d'Hebron University Hospital
Country Spain 
Sector Hospitals 
PI Contribution Tissues and mitochondria from Wt and Mpv17 KO mice
Collaborator Contribution Analysis of mitochondrial subfractions
Impact Abstract for meetings. Consortium organization for the study of mitochondrial DNA depletion and deletions Syndromes.
Start Year 2018
 
Description Manipulating the selection of mtDNA variants 
Organisation Newcastle University
Department Wellcome Trust Centre for Mitochondrial Research
Country United Kingdom 
Sector Academic/University 
PI Contribution Investigating the effects of a small molecule on the level of mutated mtDNA and mitochondrial respiration.
Collaborator Contribution Recruitment of patients and their clinical assessment and follow up
Impact To determine whether the compound that works in in vitro systems is also effective in vivo.
Start Year 2018
 
Description Manipulating the selection of mtDNA variants 
Organisation The Lily Foundation
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Investigating the effects of a small molecule on the level of mutated mtDNA and mitochondrial respiration.
Collaborator Contribution Recruitment of patients and their clinical assessment and follow up
Impact To determine whether the compound that works in in vitro systems is also effective in vivo.
Start Year 2018
 
Description Manipulating the selection of mtDNA variants 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution Investigating the effects of a small molecule on the level of mutated mtDNA and mitochondrial respiration.
Collaborator Contribution Recruitment of patients and their clinical assessment and follow up
Impact To determine whether the compound that works in in vitro systems is also effective in vivo.
Start Year 2018
 
Description Manipulating the selection of mtDNA variants 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Investigating the effects of a small molecule on the level of mutated mtDNA and mitochondrial respiration.
Collaborator Contribution Recruitment of patients and their clinical assessment and follow up
Impact To determine whether the compound that works in in vitro systems is also effective in vivo.
Start Year 2018
 
Description Measurement of metabolites 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Tissues samples from WT and Mpv17 KO mice
Collaborator Contribution Determination of metabolites in several tissues
Impact The effect of mtDNA perturbation on cellular metabolism
Start Year 2018
 
Description Molecular basis of mitochondrial disorders 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution Characterization of the biochemical and molecular phenotypes in patient-derived cells and tissues
Collaborator Contribution The partners have identified new genes likely causative of human disorders. They have provided cell lines and tissues from affected patients
Impact Changes in mitochondrial metabolism supportive of the functional role of the causative genes. Papers in high profile journal
Start Year 2016
 
Description Molecular basis of mitochondrial myopathy 
Organisation Newcastle University
Department Mitochondrial Research Group
Country United Kingdom 
Sector Academic/University 
PI Contribution In situ analysis of mtDNA distribution and the cellular response to mitochondrial DNA instability
Collaborator Contribution Providing muscle biopsy from subjects with mtDNA disorders and controls
Impact Identification of processes and pathways supporting the genesis and propagation of mutant mtDNA. Publication in journal of high profile.
Start Year 2019
 
Description Molecular basis of mitochondrial myopathy 
Organisation Newcastle University
Department Wellcome Trust Centre for Mitochondrial Research
Country United Kingdom 
Sector Academic/University 
PI Contribution Muscle samples from WT and KO mice
Collaborator Contribution Histology and Immunohistochemistry
Impact Time course of muscle pathology in a murine model of a mtDNA related disoder
Start Year 2018
 
Description New causative genes of mitochondrial disorders 
Organisation Newcastle University
Department Wellcome Trust Centre for Mitochondrial Research
Country United Kingdom 
Sector Academic/University 
PI Contribution Characterization of the biochemical and molecular phenotypes in patient-derived cells and tissues
Collaborator Contribution The partners have identified new genes likely causative of human disorders. They have provided cell lines and tissues from affected patients
Impact Changes in mitochondrial metabolism supportive of the functional role of the causative genes. PMID: 31600844 PMID: 36055214 PMID: 33742325 PMID: 31039582
Start Year 2017
 
Description New causative genes of mitochondrial disorders 
Organisation Ospedale Pediatrico Bambino Gesu (OPBG)
Country Italy 
Sector Academic/University 
PI Contribution Characterization of the biochemical and molecular phenotypes in patient-derived cells and tissues
Collaborator Contribution The partners have identified new genes likely causative of human disorders. They have provided cell lines and tissues from affected patients
Impact Changes in mitochondrial metabolism supportive of the functional role of the causative genes. PMID: 31600844 PMID: 36055214 PMID: 33742325 PMID: 31039582
Start Year 2017
 
Description New causative genes of mitochondrial disorders 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Characterization of the biochemical and molecular phenotypes in patient-derived cells and tissues
Collaborator Contribution The partners have identified new genes likely causative of human disorders. They have provided cell lines and tissues from affected patients
Impact Changes in mitochondrial metabolism supportive of the functional role of the causative genes. PMID: 31600844 PMID: 36055214 PMID: 33742325 PMID: 31039582
Start Year 2017
 
Description Nucleoside-based therapy for mtDNA disorders 
Organisation Zogenix Inc
Department Modis Therapeutics
Country United States 
Sector Private 
PI Contribution Testing the effect of modified molecules on mtDNA dysfunction in a mouse model of mtDNA depletion
Collaborator Contribution Developed modified compounds that increase in vivo bioaviability
Impact Ongoing analysis
Start Year 2019
 
Description Pathophisiological consequences of mitochondrial DNA replication defects 
Organisation Helmholtz Association of German Research Centres
Department Helmholtz Zentrum Munchen
Country Germany 
Sector Academic/University 
PI Contribution Characterization of the consequences of mtDNA dysfunction in vitro and in vivo
Collaborator Contribution Study of the calcium metabolism in cell and mouse models of mtDNA dysfunction
Impact Identification of specific perturbation of calcium metabolism
Start Year 2022
 
Description Pharmacological manipulation of mitochondrial DNA selection 
Organisation Newcastle University
Department Newcastle University Medical School
Country United Kingdom 
Sector Academic/University 
PI Contribution Identification of small molecules that select functional mitochondrial genomes
Collaborator Contribution Providing cells from patients with mitochondrial DNA disorders
Impact Publication, PMID:34873176 Patent, GB2116499.1.
Start Year 2016
 
Description Pharmacological manipulation of mitochondrial DNA selection 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Identification of small molecules that select functional mitochondrial genomes
Collaborator Contribution Providing cells from patients with mitochondrial DNA disorders
Impact Publication, PMID:34873176 Patent, GB2116499.1.
Start Year 2016
 
Description Physiopathology of mtDNA disorders 
Organisation Centre for Cooperative Research in Biomaterials (CIC BiomaGUNE)
Country Spain 
Sector Academic/University 
PI Contribution 1)Pathological characterization of a mouse model of mtDNA disorder 2) Identification of a small molecule ( 2-Deoxy-D-Glucose, 2DG) that promote the propagation of the functional mitochondrial DNA in models of disorders where mutant and wild-type mitochondrial genomes coexist.
Collaborator Contribution Imagining in an in vivo model of mtDNA disorders Imaging and tissues analyses of control mice treated with 2DG
Impact -Publication, PMID:35478201 -The collaboration involves molecular biology, imaging, omic studies (proteomic)
Start Year 2019
 
Description Ribonucleotide incorporation in mtDNA 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Purified mtDNA from mouse tissues and culture cells for sequencing analysis
Collaborator Contribution Sequencing of the mtDNA using a new approach developed by the collaborators (Emboriboseq) and analysis of the data
Impact Identification of the identity and distribution of the ribonucleotide incorporated in mtDNA of normal tissues and cells. Identification of a new mtDNA abnormality, aberrant ribonucleotide incorporation, in tissues of the Mpv17 KO mouse. Paper in journal of high profile (PMID:29106596)
Start Year 2016
 
Title Compounds for the treatment of heteroplasmic mitochondrial DNA disorders 
Description Compounds for the treatment of mitochondrial DNA disorders 
IP Reference GB2116499.1. 
Protection Patent application published
Year Protection Granted 2021
Licensed No
Impact Pharmacompanies are interested in licensing the patent. This could lead to investments on basic research and clinical trials
 
Description ENMC, Heemskerk, The Netherlands. 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact The 232nd ENMC International Workshop held in Heemskerk, The Netherlands in June 2017. Among the participant were expert in the field of mDNA metabolism, relatives of patients and members of biopharmaceutical companies. The aims of the workshop were to identify actions needed to advance the clinical recognition, diagnosis, and treatment of patients suffering from disorders of mtDNA maintenance. Clear guidelines were issued.
Year(s) Of Engagement Activity 2017
 
Description Gdansk, 17th symposium on Purine and Pyrimidine in Man 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact I was invited to give a presentation as leader in the field in mtDNA disorders. The new findings stimulated interest in the research topic. Novel collaborations started after the meeting.
Year(s) Of Engagement Activity 2017
 
Description Invited speaker at an International scientific meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact AS presented her group progress in developing potential treatments for mitochondrial DNA disorders.
Year(s) Of Engagement Activity 2022
 
Description Invited speaker at an International scientific meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact AS presented the progress her group has made in developing potential treatments for mitochondrial DNA disorders.
Year(s) Of Engagement Activity 2022
 
Description MEET final meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact My group organized the final event of the Mitocondrial European Education and Training (MEET) in London ( 12 Dec 2016).

The event included a scientific conference with eminent speakers from the mitochondria - and non - community, and a dissemination part.
Year(s) Of Engagement Activity 2016
 
Description Mitochondrial Conferences; Seminar to Universities 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Invitation to King's College to give a seminar (2015).
Invitation to Newcastle University to give a seminar ( 2014).
Year(s) Of Engagement Activity 2014,2015
 
Description Patient group workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact AS presented, during an online meeting, the group progress in developing potential treatments for mitochondrial DNA disorders.
Year(s) Of Engagement Activity 2020
 
Description Seminar to Neurological Institute Besta 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact AS presented, during an online meeting, the group progress in developing potential treatments for mitochondrial DNA disorders.
Year(s) Of Engagement Activity 2022
 
Description UK Neuromuscular Translational Research Conference 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact AS was invited to give a presentation on her latest research on mtDNA selection and one of her fellow was selected for a poster presentation.
Both presentations stimulated increased interest in the research topic.
Year(s) Of Engagement Activity 2019